
Unicycive Therapeutics (UNCY) Stock Forecast & Price Target
Unicycive Therapeutics (UNCY) Analyst Ratings
Bulls say
Unicycive Therapeutics Inc. is well-positioned for growth with its lead product candidate, Oxylanthanum Carbonate (OLC), which offers a convenient dosing regimen that may enhance patient compliance among approximately 500,000 individuals treated for hyperphosphatemia in the United States. Furthermore, the company's pipeline includes UNI-494, a new chemical entity with the potential to become a first-in-class treatment for Acute Kidney Injury, suggesting significant upside in Unicycive's market opportunities as the drug progresses through development. Additionally, analysts exhibit confidence in the company's trajectory, recognizing an expected improvement in market valuation as evidenced by a substantial increase in the proposed price target, indicating a positive outlook for Unicycive's stock.
Bears say
Unicycive Therapeutics has consistently incurred operating losses since its inception, indicating challenges in achieving profitability in the foreseeable future. Furthermore, pressures related to healthcare spending and potential unfavorable changes in reimbursement policies could adversely impact the company's financial performance and revenue projections. Additionally, the company is anticipated to require further capital to support its operations and development efforts, raising concerns about its long-term financial stability.
This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Unicycive Therapeutics (UNCY) Analyst Forecast & Price Prediction
Start investing in Unicycive Therapeutics (UNCY)
Order type
Buy in
Order amount
Est. shares
0 shares